Amgen price target lowered to $317 from $326 at UBS

UBS analyst Trung Huynh lowered the firm’s price target on Amgen (AMGN) to $317 from $326 and keeps a Neutral rating on the shares. Amgen delivered a solid Q2 print, with total sales 3% ahead of consensus and broad beats across product segments, the analyst tells investors in a research note. UBS thinks the Q2 performance on the top-line should continue to instill confidence in fundamentals.